Therapeutic nucleic acid-3' -conjugates

Details Therapeutic nucleic acid-3' -conjugates Therapeutic nucleic acid-3' -conjugates

2011-03-22

2011-03-22

Chong, Kimberly (Department: 1635)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C435S325000, C435S375000, C536S024500, C536S024310, C536S024100

Reexamination Certificate

active

07910297

ABSTRACT:
Methods are described for improvement of the serum half life of therapeutic nucleic acids by 3′ conjugation to useful target proteins, or other large molecules with useful function. In one embodiment, a 3′ A, C or G overhang is added to ds-DNA and the primary amines conjugated using biocompatible bifunctional linkers to proteins. The resulting nucleic acid-3′-conjugates are serum nuclease-resistant and retained in vivo for long periods without rapid kidney clearance. Further, the choice of conjugate imparts additional functionality to the nucleic acid-3-conjugate.For example, if the protein in the DNA-protein conjugate is the first component of the complement cascade (Clq or Clqrs) and the DNA aptamer has been developed against surface components of a target cell, it can be used to treat bacterial or parasitic infections and cancers. If the protein is serum albumin or another common (nonimmunogenic) blood protein and the aptamer is directed against a toxin or venom, the aptamer-protein conjugate can be used as an antidote that binds and neutralizes the toxin or venom. Similar DNA (aptamer)-nanotube, -enzyme, and -toxin conjugates could also be used to target and selectively kill bacteria, parasites, and cancer cells in vivo. If the protein is an Fc antibody fragment or C3b protein from the complement system and the aptamer is developed against a bacterial cell capsular material, other cell surface component or viral cell surface component, then the aptamer-3′-protein conjugate can aid in opsonization of the target cells or viruses by phagocytic leukocytes.

REFERENCES:
patent: 5270163 (1993-12-01), Gold et al.
patent: 5475096 (1995-12-01), Gold et al.
patent: 5573913 (1996-11-01), Rosemeyer et al.
patent: 6127119 (2000-10-01), Stephens et al.
patent: 6172208 (2001-01-01), Cook
patent: 6235886 (2001-05-01), Manoharan et al.
patent: 6566343 (2003-05-01), Biesecker et al.
patent: 6623926 (2003-09-01), Lohse et al.
patent: 6780850 (2004-08-01), Dougan et al.
Petrie et al. An Improved CPG Support for the Synthesis of 3' amine-tailed oligonucleotides. Bioconjugate chem. 192, vol. 3: 85-87.
Martin et al. Tailing and 3'-end labeling of RNA with yeast poly(a) polymerase and various nucleotides. RNA, 1998, vol. 4: 226-230.
Bell, et al., “Oligonucleotide NX1838 Inhibits VEGF165-Mediated Cellular Responses In Vitro,” In Vitro Cell Develop.Biol Animal. (1999) 35:533-542.
Biesecker, et al., “Derivation of RNA Aptamer Inhibitors of Human Complement C5,” Immunopharm (1999) 42:219-230.
Blank, et al. “Systematic Evolution of a DNA Aptamer Binding to Rat Brain Tumor Microvessels, Selective Targeting of Endothelial Regulatory Protein Pigpen,” J. Biol. Chem. (2001) 276:16464-16468.
Brody, E.N. and Gold, L., “Aptamers as Therapeutic and Diagnostic Agents,” Reviews in Mol. Biotechnol. (2000), 74:5-13.
Bruno, In Vitro Selection of DNA to Chloroaromatics Using Magnetic Microbead-Based Affinity Separation and Fluorescence Detection, Biochem. Biophys. Res. Comm. (1997) 234: 117-120.
Bruno and Kiel, “In Vitro Selection of DNA Aptamers to Anthrax Spores with Electrochemiluminescence Detection,” Biosensors & Bioelectronics (1999) 14:457-464.
Bruno and Kiel, “Use of Magnetic Beads in Selection and Detection of Biotoxin Aptamers by ECL and Enzymatic Methods,”BioTechniques (2002) 32:178-183.
Dougan, et al., “Extending the Lifetime of Anticoagulant Oligodeoxynucleotide Aptamers in Blood,” Nuclear Med. Biol. (2000) 27:289-297.
Drolet, et al., “Pharmacokinetics and Safety of an Anti-Vascular Endothelial Growth Factor Aptamer (NX1838) Following Injection into the Vitreous Humor or Rhesus Monkeys,” (2000) Pharm. Res. 17:1503-1510.
Hicke, et al., “Tenascin-C Aptamers are generated Using Tumor Cells and Purified Protein,” J. Biol. Chem. (2001) 276:48644-48654.
Homann and Goringer, “Uptake and Intracellular Transport of RNA Aptamers in African Trypanosomes Suggest Therapeutic ‘Piggy-Back’ Approach,” Bioorg. Med. Chem (2001) 9:2571-2580.
Huang, et al., “Highly Specific Antiangiogenic Therapy is Effective in Suppressing Growth of Experimental Wilms Tumors,” J. Pediatric. Surg. (2001) 36:357-361.
Murphy, et al., “An Improved Method for the In Vitro Evolution of Aptamers and Applications in protein Detection and Purification,” Nucleic Acids Res. (2003) 31:e110-e118.
Ono, T, et al.,“2'-Fluoro Modified Nucleic Acids: Polymerase-Directed Synthesis, Properties and Stability to Analysis by Matrix Assisted Laser Desorption/I onization Mass Spectrometry,” Nucl. Acids Res. (1997), 25:4581-4588.
Ruckman, J., et al., “2'-Fluropyrimidine RNA-Based Aptamers to the 165 Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165),” J. Biol. Chem. (1998) 273:20556-20567.
Ulrich, et al., “In Vitro Selection of RNA Aptamers that Bind the Cell Adhesion Receptors ofTrypanosoma cruziand inhibit cell invasion,” J. Biol. Chem. (2002) 277:20756-20762.
Welkos, et al., “The Role of Antibodies toBacillus Anthracisand Anthrax toxin components in Inhibiting the Early Stages of Infection of Anthrax Spores,” Microbiology (2001), 147:1677-1685.
Chu, Ted C., et al; Aptamer: Toxin Conjugates That Specifically Target Prostate Tumor Cells; Cancer Research; Jun. 15, 2006; pp. 5989-5992; 66(12); Am. Association for Cancer Research; Austin, TX , US.
Abe, Ikuro, et al; Enzymatic formation of unnatural cytokinin analogs by adenylate isopentenyltransferase from mulberry; Science Direct; Feb. 15, 2007; pp. 795-800; Biochemical and Biophysical Research Communications 355; www.elsevier.com/locate/ybbrc.
Zahler, Alan M., et al.; Telomere terminal transferase activity in the hypotrichous ciliate Oxytricha nova and a model for replication of the ends of linear DNA molecules; Nucleic Acids Research;1988; pp. 6953-6972; IRL Press Ltd.; Oxford, England.

Affiliated with

Also associated with

Rating

Therapeutic nucleic acid-3' -conjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic nucleic acid-3' -conjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic nucleic acid-3' -conjugates will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2716394